Andrew D Beggs
Andrew Beggs is a Professor of Cancer Genetics & Surgery in the Institute of Cancer and Genomic Sciences, University of Birmingham. He is also the Deputy Director of the Birmingham Experimental Cancer Medicine Centre and Theme Lead for Biomarkers and Liquid Biopsy. He also is Head of Somatic Cancer in the Central and South Genomic Medicine Service Alliance. He is Co-Lead of the Translational Biology and Genetics research theme within the Institute of Cancer and Genomic Sciences. He is also a Fellow of the Alan Turing Institute.
Currently funded by multiple industrial partners as well as the MRC, BBSRC, Sarcoma UK and Cancer Research UK, Andrew’s lab research encompasses organoid models of cancer, cancer biology and omics technologies in medicine. He is also a Consultant Colorectal & General Surgeon at the Queen Elizabeth Hospital in Birmingham with specialist interest in laparoscopic (keyhole) cancer surgery and familial cancer syndromes for which he runs as part of a national service. He is also an honorary consultant surgeon at Birmingham Childrens and Womens Hospitals.
His major research interests include solid tumour cancer biology and translational medicine. He has published articles in Nature, Nature Biotechnology, Nature Genetics, the BMJ, The Lancet, Gut, Journal of Pathology and PLoS Genetics. He collaborated in writing the European consensus guidelines for the management of Peutz-Jeghers syndrome.
His laboratory also has interests in method development, holding the IP on long read sequencing of the Human Leucocyte Antigen (HLA) complex of genes as well as biochemical methods of sensing SNP alleles at room temperature and rapid amplification of RNA (RTF-ExPAR). During the COVID-19 pandemic he became a scientific adviser to the DSHC on COVID-19 diagnostics and is the Chief Clinician of the LFD Digital Read programme.
His major research interests include colorectal, oesophageal and sarcoma cancer biology and translational medicine. He has published articles in The Lancet, Gut, Journal of Pathology and PLoS Genetics. He collaborated in writing the European consensus guidelines for the management of Peutz-Jeghers syndrome.
Andrew has been awarded grant funding from Cancer Research UK, Medical Research Council, Wellcome Trust, Illumina UK, Cancer Research UK, Mason Medical Research Foundation, Peel Medical Research Trust & St Georges Hospital Charity.
His current research programme is examining the molecular genetics of colorectal cancer, and has recently received programme funding from CRUK to set up organoid model systems to understand neoadjuvant chemoradiosensitivity in rectal cancer. He is also carrying out research into rare cancers using multi-omics profiling; biomarker development technologies and runs a bioinformatics “dry-lab” to search for novel therapeutic targets and stratification markers.
Supervisors: Prof Ian Tomlinson and Prof Shirley Hodgson
Phone: +44(0)121 414 6924
Address: Institute of Cancer & Genomic Science
University of Birmingham
Birmingham
B15 2TT
UK
Currently funded by multiple industrial partners as well as the MRC, BBSRC, Sarcoma UK and Cancer Research UK, Andrew’s lab research encompasses organoid models of cancer, cancer biology and omics technologies in medicine. He is also a Consultant Colorectal & General Surgeon at the Queen Elizabeth Hospital in Birmingham with specialist interest in laparoscopic (keyhole) cancer surgery and familial cancer syndromes for which he runs as part of a national service. He is also an honorary consultant surgeon at Birmingham Childrens and Womens Hospitals.
His major research interests include solid tumour cancer biology and translational medicine. He has published articles in Nature, Nature Biotechnology, Nature Genetics, the BMJ, The Lancet, Gut, Journal of Pathology and PLoS Genetics. He collaborated in writing the European consensus guidelines for the management of Peutz-Jeghers syndrome.
His laboratory also has interests in method development, holding the IP on long read sequencing of the Human Leucocyte Antigen (HLA) complex of genes as well as biochemical methods of sensing SNP alleles at room temperature and rapid amplification of RNA (RTF-ExPAR). During the COVID-19 pandemic he became a scientific adviser to the DSHC on COVID-19 diagnostics and is the Chief Clinician of the LFD Digital Read programme.
His major research interests include colorectal, oesophageal and sarcoma cancer biology and translational medicine. He has published articles in The Lancet, Gut, Journal of Pathology and PLoS Genetics. He collaborated in writing the European consensus guidelines for the management of Peutz-Jeghers syndrome.
Andrew has been awarded grant funding from Cancer Research UK, Medical Research Council, Wellcome Trust, Illumina UK, Cancer Research UK, Mason Medical Research Foundation, Peel Medical Research Trust & St Georges Hospital Charity.
His current research programme is examining the molecular genetics of colorectal cancer, and has recently received programme funding from CRUK to set up organoid model systems to understand neoadjuvant chemoradiosensitivity in rectal cancer. He is also carrying out research into rare cancers using multi-omics profiling; biomarker development technologies and runs a bioinformatics “dry-lab” to search for novel therapeutic targets and stratification markers.
Supervisors: Prof Ian Tomlinson and Prof Shirley Hodgson
Phone: +44(0)121 414 6924
Address: Institute of Cancer & Genomic Science
University of Birmingham
Birmingham
B15 2TT
UK
less
InterestsView All (16)
Uploads
Books by Andrew D Beggs
Papers by Andrew D Beggs